Intermittent fasting and triglycerides are increasingly discussed together as interest in dietary approaches to cardiovascular health grows. Triglycerides — fats circulating in the bloodstream — are a key marker of metabolic health, and persistently elevated levels raise the risk of heart disease and pancreatitis. Structured eating patterns such as the 16:8 method or the 5:2 diet may help reduce triglyceride levels, primarily by creating a calorie deficit and improving insulin sensitivity. This article explores the mechanisms behind this effect, what UK clinical evidence and NICE guidance say, who is most likely to benefit, and when to seek medical advice.

How Intermittent Fasting Affects Triglyceride Levels

Intermittent fasting reduces triglycerides primarily through overall calorie deficit, which lowers insulin-driven fat synthesis, increases lipolysis, and may reduce liver-derived triglyceride output via VLDL particles.

Intermittent fasting (IF) refers to structured eating patterns that cycle between periods of fasting and eating. Common approaches include the 16:8 method (fasting for 16 hours, eating within an 8-hour window), the 5:2 diet (eating normally for five days and restricting calories to around 500–600 kcal on two non-consecutive days), and alternate-day fasting. Each of these approaches influences how the body processes and stores fat, which has direct implications for triglyceride levels.

Triglycerides are a type of fat (lipid) found in the bloodstream. After eating, the body converts unused calories — particularly from carbohydrates and fats — into triglycerides, which are stored in fat cells and released for energy between meals. Persistently elevated triglycerides (hypertriglyceridaemia) are associated with an increased risk of cardiovascular disease and pancreatitis.

It is important to note that the primary driver of triglyceride reduction with intermittent fasting is overall energy deficit and weight loss, rather than the timing of meals per se. Where IF does produce a calorie deficit, several metabolic changes may contribute to lower circulating triglycerides:

• Reduced insulin secretion during fasting periods may limit new triglyceride production, as insulin promotes triglyceride synthesis

• Increased lipolysis (fat breakdown) mobilises stored triglycerides from adipose tissue; sustained over time, this can reduce overall fat stores

• Decreased caloric intake reduces the availability of substrates for triglyceride synthesis

• Possible improvements in hepatic fat metabolism may reduce liver-derived triglyceride output (via VLDL particles), though this effect varies by IF pattern, degree of energy deficit, and individual response

These mechanisms provide a plausible biological basis for the lipid-lowering effects observed in some clinical studies, but the magnitude of benefit depends heavily on whether a meaningful energy deficit is achieved and maintained.

What the Evidence Says: Clinical Trials and Current UK Guidance

Clinical trials show IF can reduce fasting triglycerides by roughly 10–20% over 8–24 weeks in overweight individuals, but NICE NG238 does not currently endorse any specific IF protocol for hypertriglyceridaemia.

A growing body of clinical research supports the role of intermittent fasting in reducing triglyceride levels, though the quality and consistency of evidence varies. A 2020 systematic review and meta-analysis published in Obesity Reviews found that intermittent fasting was associated with statistically significant reductions in fasting triglycerides in some trials, with reported decreases typically in the range of 10–20% over periods of 8–24 weeks in people who were overweight or had metabolic syndrome at baseline. Effect sizes varied considerably across studies, and results should be interpreted with caution given differences in trial design, population, and duration.

The 5:2 diet has been evaluated in several randomised controlled trials, including research from the University of Manchester, which demonstrated that the 5:2 approach produced broadly comparable reductions in triglycerides and other cardiovascular risk markers when compared with continuous caloric restriction. This suggests that the overall energy deficit, rather than the specific pattern of restriction, may be the dominant factor — though some researchers propose additional metabolic benefits from the fasting periods themselves. Evidence for this remains uncertain.

From a guidance perspective, NICE (National Institute for Health and Care Excellence) does not currently endorse any specific intermittent fasting protocol as a first-line treatment for hypertriglyceridaemia. The current relevant guideline is NICE NG238 (Lipids: management of blood lipids, 2023), which supersedes the earlier CG181. NG238 emphasises lifestyle modification (diet, physical activity, and weight management), addresses triglyceride testing thresholds, and provides advice on when specialist referral is appropriate. Pharmacological intervention is considered where lifestyle measures are insufficient, particularly for cardiovascular risk reduction or to reduce the risk of pancreatitis in severe hypertriglyceridaemia.

The NHS supports dietary approaches to weight management, which in turn can improve lipid profiles, but does not endorse a specific IF protocol. The British Dietetic Association (BDA) provides a balanced patient-facing overview of IF approaches and their suitability in its Food Fact Sheet on intermittent fasting.

Most trials have been relatively short in duration and conducted in specific populations. Long-term data on sustained triglyceride reduction through intermittent fasting remain limited, and further large-scale, well-controlled studies are needed before definitive clinical recommendations can be made.

Who May Benefit Most From Intermittent Fasting

People who are overweight, have metabolic syndrome, or have diet-driven elevated triglycerides are most likely to benefit; those with secondary causes such as hypothyroidism or genetic conditions typically require additional medical management.

Not everyone with elevated triglycerides will respond equally to intermittent fasting, and identifying those most likely to benefit is clinically important. Current evidence suggests that certain groups may experience more meaningful reductions in triglyceride levels through this dietary approach.

People who are overweight or obese tend to show the greatest improvements. Excess adipose tissue — particularly visceral (abdominal) fat — is a major driver of elevated triglycerides, and weight loss achieved through intermittent fasting directly addresses this underlying cause. Even modest weight loss of 5–10% of body weight has been shown to produce clinically significant reductions in triglyceride levels.

Individuals with metabolic syndrome — a cluster of conditions including central obesity, raised blood glucose, high blood pressure, and dyslipidaemia — may also benefit substantially. Intermittent fasting appears to improve insulin sensitivity, reduce fasting glucose, and lower triglycerides simultaneously, making it a potentially useful intervention for this group.

Additionally, those whose elevated triglycerides are primarily driven by dietary factors, such as high refined carbohydrate or alcohol intake, may respond well to the structured restriction that intermittent fasting provides. By naturally limiting the window during which food is consumed, many people inadvertently reduce their intake of processed foods and sugary drinks.

Conversely, individuals with triglyceride elevations caused by secondary causes — including hypothyroidism, type 2 diabetes, chronic kidney disease, nephrotic syndrome, alcohol excess, or certain medications (such as corticosteroids, retinoids, antiretrovirals, and oestrogens) — may see more limited benefits from dietary changes alone. It is important that these underlying causes are identified and addressed before or alongside any dietary intervention. Similarly, those with genetic conditions such as familial hypertriglyceridaemia are likely to require additional medical management.

A healthcare professional should always be involved in assessing the underlying cause of elevated triglycerides before initiating any dietary intervention.

Risks and Considerations for People With High Triglycerides

Triglycerides above 10 mmol/L carry a risk of acute pancreatitis requiring urgent medical review; people with diabetes, disordered eating history, or who are pregnant should not start IF without professional guidance.

Whilst intermittent fasting can offer metabolic benefits, it is not without risks — particularly for individuals with significantly elevated triglycerides or underlying health conditions. Understanding these considerations is essential before embarking on any fasting regimen.

Severely elevated triglycerides (above 10 mmol/L) carry a risk of acute pancreatitis, a potentially life-threatening condition. In line with NICE NG238, if non-fasting triglycerides exceed 10 mmol/L, a fasting repeat test should be arranged within two weeks, and specialist input sought if levels remain persistently high. Dietary intervention alone is insufficient in this context, and urgent medical management is required. Symptoms that may suggest acute pancreatitis — including severe upper abdominal pain radiating to the back, nausea, and vomiting — require emergency medical attention (call 999 or go to A&E).

For individuals with type 1 or type 2 diabetes, fasting periods can cause unpredictable fluctuations in blood glucose and may increase the risk of hypoglycaemia, particularly in those taking insulin or sulphonylureas. Any dietary change in this group should be discussed with a GP or diabetes specialist before implementation.

Other important considerations include:

• Disordered eating history: Structured fasting may trigger or exacerbate restrictive eating behaviours in susceptible individuals

• Pregnancy and breastfeeding: Caloric restriction is not appropriate during these periods and may adversely affect foetal or infant nutrition

• Children and adolescents: Intermittent fasting is not appropriate for those under 18 unless under specialist supervision

• Underweight individuals: Fasting regimens are not suitable for those with a low body weight or at risk of malnutrition

• Older adults: Prolonged fasting may increase the risk of muscle loss (sarcopenia) and nutritional deficiencies

• Medication timing: Some medications must be taken with food, and fasting windows may interfere with dosing schedules — always check with a pharmacist or GP

It is also worth noting that the quality of food consumed during eating windows matters considerably. A fasting regimen that permits high-fat, high-sugar foods during eating periods is unlikely to produce meaningful triglyceride reductions and may worsen the lipid profile overall.

Combining Intermittent Fasting With Other Lifestyle Changes

Intermittent fasting is most effective alongside at least 150 minutes of weekly aerobic exercise, a Mediterranean-style diet, and reduced alcohol intake; fibrates or omega-3 ethyl esters may be added under specialist advice for persistent cases.

Intermittent fasting is most effective when integrated into a broader lifestyle strategy rather than adopted in isolation. Evidence consistently shows that combining dietary modification with other health-promoting behaviours produces greater and more sustained reductions in triglyceride levels.

Physical activity is one of the most powerful tools for lowering triglycerides. Aerobic exercise — such as brisk walking, cycling, or swimming — increases the activity of lipoprotein lipase, an enzyme that breaks down triglycerides in the bloodstream. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, and this target remains relevant for those managing dyslipidaemia. When combined with intermittent fasting, regular exercise may amplify the lipid-lowering effect by further improving insulin sensitivity and promoting fat oxidation.

Dietary quality during eating windows is equally important. A Mediterranean-style diet — rich in vegetables, legumes, wholegrains, oily fish, and olive oil, and low in refined carbohydrates and saturated fats — has robust evidence supporting its role in reducing cardiovascular risk and improving lipid profiles. Reducing alcohol intake is also particularly relevant, as alcohol is a significant and often underappreciated driver of hypertriglyceridaemia.

Smoking cessation should be encouraged in all patients with cardiovascular risk factors, including those with elevated triglycerides. Smoking adversely affects lipid metabolism and compounds the cardiovascular risk associated with dyslipidaemia.

For some individuals, pharmacological therapy may be required alongside lifestyle changes. In line with NICE NG238, fibrates (such as fenofibrate) and omega-3-acid ethyl esters (for example, Omacor) are licensed in the UK as adjuncts to diet for the treatment of hypertriglyceridaemia, and are typically initiated under specialist advice for severe or persistent cases. Their use is not routinely recommended for general cardiovascular disease prevention. It is important to note that icosapent ethyl (Vazkepa) is not licensed for treating hypertriglyceridaemia; in the UK it is indicated for cardiovascular risk reduction in specific statin-treated patients with elevated triglycerides, as assessed under NICE Technology Appraisal TA805.

If you are prescribed any medicine for your lipid levels and experience a suspected side effect, you can report this to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Intermittent fasting and medication are not mutually exclusive and can be used concurrently under medical supervision.

When to Seek Medical Advice About Your Triglyceride Levels

See your GP if triglycerides exceed 5 mmol/L, or urgently if above 10 mmol/L or if you develop severe upper abdominal pain, as these thresholds require clinical review in line with NICE NG238.

Knowing when to consult a healthcare professional is an important aspect of managing triglyceride levels safely. Whilst mild elevations may respond well to lifestyle changes including intermittent fasting, certain situations warrant prompt medical assessment.

You should contact your GP if:

• Your triglyceride level has been measured above 5 mmol/L, as this warrants clinical review, investigation of secondary causes, and consideration of further management

• Your triglyceride level is above 10 mmol/L — in this case, a fasting repeat test should be arranged within two weeks and specialist input sought if levels remain high, in line with NICE NG238

• You experience symptoms that may suggest acute pancreatitis, including severe upper abdominal pain radiating to the back, nausea, and vomiting — this requires emergency medical attention

• You have a family history of premature cardiovascular disease or known familial hyperlipidaemia

• You are considering intermittent fasting but have diabetes, kidney disease, liver disease, or are taking medications that affect blood glucose or lipid metabolism

• You have been following a healthy diet and exercise programme for three to six months without meaningful improvement in your lipid levels

In UK primary care, lipid profiles are typically measured using a non-fasting blood test as the first-line approach. A fasting test is reserved for situations where non-fasting triglycerides are very high (above 10 mmol/L) or where a clinician specifically requests it. Your GP can arrange this as part of a routine cardiovascular risk assessment.

In the UK, NHS Health Checks — offered to adults aged 40–74 — include cardiovascular risk assessment and lipid screening, providing an accessible entry point for identifying dyslipidaemia. Details are available on the NHS website.

If your GP identifies persistently elevated triglycerides, you may be referred to a lipid clinic, endocrinology, or metabolic medicine service, depending on local pathways. Your GP can advise on whether dietary approaches are appropriate for your individual circumstances and whether pharmacological treatment is indicated.

Ultimately, intermittent fasting may be a valuable tool in managing triglyceride levels for many people, but it should complement — not replace — professional medical guidance and evidence-based treatment.

Frequently Asked Questions